Influenza A virus H7N9 viral antigens (H7N9 antigens)

The H7N9 viral antigens primarily comprise the surface glycoproteins Hemagglutinin (HA) and Neuraminidase (NA) of the Influenza A virus subtype H7N9. Hemagglutinin (H7) mediates the initial stages of infection by binding to sialic acid receptors on the host cell surface and facilitating membrane fusion for viral entry (CDC, 2021). Neuraminidase (N9) is an enzyme that cleaves sialic acid residues, allowing newly synthesized virions to be released from the host cell to infect adjacent cells (WHO, 2019). These antigens are the primary targets for neutralizing antibodies and are the central components of H7N9 vaccine candidates designed to prevent severe respiratory disease and potential pandemics (PubMed, 2013). Antiviral drugs such as oseltamivir and zanamivir specifically target the N9 neuraminidase to inhibit viral replication, although the emergence of resistance mutations like R292K remains a significant clinical concern (Nature, 2013). Because H7N9 is a zoonotic virus with high mortality rates in humans, these antigens are critical focal points for both diagnostic surveillance and therapeutic intervention.

Other names

H7N9 surface proteinsH7N9 glycoproteinsHemagglutinin H7Neuraminidase N9H7N9 HA/NA proteins

Neuraminidase inhibitors (e.g., oseltamivir, zanamivir) bind to the active site of the N9 protein to prevent the cleavage of sialic acid, thereby trapping progeny virions on the host cell surface; vaccines induce neutralizing antibodies that bind to the H7 hemagglutinin to block viral attachment and entry into host cells.